Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Physiologically based pharmacokinetic (PBPK) models can be used to leverage physiological and in vitro data to predict monoclonal antibody (mAb) concentrations in serum and tissues. However, it is currently not known how consistent predictions of mAb disposition are across PBPK modelling platforms. In this work PBPK simulations of IgG, adalimumab and infliximab were compared between three platforms (Simcyp, PK-Sim, and GastroPlus). Accuracy of predicted serum and tissue concentrations was assessed using observed data collected from the literature. Physiological and mAb related input parameters were also compared and sensitivity analyses were carried out to evaluate model behavior when input values were altered. Differences in serum kinetics of IgG between platforms were minimal for a dose of 1 mg/kg, but became more noticeable at higher dosages (> 100 mg/kg) and when reference (healthy) physiological input values were altered. Predicted serum concentrations of both adalimumab and infliximab were comparable across platforms, but were noticeably higher than observed values. Tissue concentrations differed remarkably between the platforms, both for total- and interstitial fluid (ISF) concentrations. The accuracy of total tissue concentrations was within a three-fold of observed values for all tissues, except for brain tissue concentrations, which were overpredicted. Predictions of tissue ISF concentrations were less accurate and were best captured by GastroPlus. Overall, these simulations show that the different PBPK platforms generally predict similar mAb serum concentrations, but variable tissue concentrations. Caution is therefore warranted when PBPK models are used to simulate effect site tissue concentrations of mAbs without data to verify the predictions.
Overview
CoChat Summary
TL;DR
This paper compares monoclonal antibody disposition predictions across three PBPK platforms—Simcyp, PK-Sim, and GastroPlus—for IgG, adalimumab, and infliximab. The platforms gave broadly similar serum predictions but substantially different tissue predictions, so the authors caution against using tissue-effect-site predictions without verification.
Key findings
- For IgG, serum kinetics were “minimal” across platforms at 1 mg/kg, but differences became more noticeable at doses >100 mg/kg and when healthy reference physiological inputs were altered.
- Predicted serum concentrations of adalimumab and infliximab were comparable across platforms, but were “noticeably higher” than observed values.
- Tissue concentrations differed “remarkably” across platforms for both total tissue and interstitial fluid (ISF) concentrations.
- Total tissue concentration predictions were within a three-fold of observed values for all tissues except brain, which was overpredicted; ISF predictions were less accurate and were best captured by GastroPlus.
Methods
- Comparative PBPK simulation study across three modeling platforms: Simcyp, PK-Sim, and GastroPlus.
- Simulated IgG, adalimumab, and infliximab using physiological and mAb-related input parameters; observed serum and tissue data were collected from the literature for comparison.
- Performed sensitivity analyses to evaluate model behavior when input values were altered.
Limitations
- Stated by the paper: prediction accuracy for tissue ISF concentrations was lower than for total tissue concentrations, and these were only “best captured by GastroPlus.”
- Stated by the paper: caution is warranted when PBPK models are used to simulate effect-site tissue concentrations of mAbs without data to verify the predictions.
- Evident from the text: the study relies on observed data collected from the literature rather than a single standardized experimental dataset, which may limit direct comparability across outputs.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 0 Not checked · 17 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Predictions of tissue ISF concentrations were less accurate and were best captured by GastroPlus.”
§ 2 files | 18.09 MB > 12.28 MB
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Differences in serum kinetics of IgG between platforms were minimal for a dose of 1 mg/kg, but became more noticeable at higher dosages (> 100 mg/kg) and when reference (healthy) physiological input values were altered.”
§ 2 files | 18.09 MB > 12.28 MB
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Differences in serum kinetics of IgG between platforms were minimal for a dose of 1 mg/kg, but became more noticeable at higher dosages (> 100 mg/kg) and when reference (healthy) physiological input values were altered.”
§ 2 files | 18.09 MB > 12.28 MB
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Predicted serum concentrations of both adalimumab and infliximab were comparable across platforms, but were noticeably higher than observed values.”
§ 2 files | 18.09 MB > 12.28 MB
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The accuracy of total tissue concentrations was within a three-fold of observed values for all tissues, except for brain tissue concentrations, which were overpredicted.”
§ 2 files | 18.09 MB > 12.28 MB
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 17 claims and every source verdict.
- Probably not a substantial claim. 2
Citations
Cites
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line
Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 434
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Garg, A., & Balthasar, J. P. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9065-1 · Cited by 327
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell, D. G., Barbet, J., Holton, O. D., BLACK, C. D. V., Parker, R. J., & Weinstein, J. N. (1986) · PubMed · Cited by 311
Weisman, M. H., Moreland, L. W., Furst, D. E., Weinblatt, M. E., Keystone, E. C., Paulus, H. E., Teoh, L. S., Velagapudi, R. B., Noertersheuser, P. A., Granneman, G. R., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80164-9 · Cited by 303
Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 284
Research works printed but not linked: 1
- den Broeder A, van de Putte L, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288–2298
Cited by
Patidar, K., Pillai, N., Dhakal, S., Avery, L. B., & Mavroudis, P. D. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09899-z · Cited by 11
Vallejo, C., Meaney, C., Clemens, L., Yang, K., Lukáčová, V., & Zhou, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030372 · Cited by 2
Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies
Fan, X., Chen, C., Zhang, L., Cao, K., & Yan, X. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115850 · Cited by 3
Wal, P., Dwivedi, J., Pandey, K., Sharma, K. K., Tiwari, M., Ali, M. S., Khan, A., & Gasmi, A. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109120 · Cited by 6
Massaux, C., Dogné, J.-M., & Musuamba, F. T. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-00988-1 · Cited by 2
“Between-platform differences in PBPK predictions have also been described for biologics by De Sutter et al. [25].”
Metadata
- Authors
- De Sutter, P.-J., Gasthuys, E., & Vermeulen, A.
- Affiliations
- Ghent University (BE)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2023-11-12
- Volume
- 51
- Issue
- 6
- Pages
- 639-651
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W4388603732
- Semantic Scholar
- 1f3a8dfeb1bd2e62b926294faab7e0a9f2993b6a
- Cited by
- 8
- References
- 34
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
- biblio.ugent.be
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- monoclonal antibodies, physiologically based pharmacokinetic modeling, adalimumab, infliximab, IgG, tissue distribution, brain tissue concentration, SimCYP, PK-Sim, GastroPlus, sensitivity analysis
- MeSH terms
- Adalimumab, Infliximab, Antibodies, Monoclonal, Computer Simulation, Humans, Immunoglobulin G, Models, Biological, Tissue Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms. https://app.cochat.ai/papers/10.1007/s10928-023-09894-4
- The paper
- De Sutter, P.-J., Gasthuys, E., & Vermeulen, A. (2024). Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-023-09894-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.